Sarcopenia in the ICU - Key Recent Articles

1. Meta-Analyses & Systematic Reviews (Highest Evidence)

• 25 studies, 12,347 patients
• Sarcopenic ICU patients had 2.28x higher odds of mortality (95% CI: 1.83-2.83)
• In COVID-19 patients, low skeletal muscle mass raised in-hospital mortality OR to 5.84
• CT muscle measurements correlated inversely with CRP (r = -0.315), fibrinogen (r = -0.392), and D-dimers
• Combined CT-sarcopenia + inflammatory marker models outperformed APACHE II, SOFA, CURB-65, and PSI scoring systems

• Highlights the 2023 EWGSOP2 update emphasizing muscle strength over mass as the primary sarcopenia criterion - this is challenging to assess in sedated/intubated ICU patients
• Clinical Frailty Scale (CFS) remains the most used frailty tool in ICU
• Frailty worsens by hospital discharge but improves by 6 months post-ICU
• Multidimensional interventions (patient-tailored mobilization + nutrition) are most promising
• No unified sarcopenia definition exists for the ICU setting - a major research gap

• 8 prospective cohort studies, 411 critically ill children
• Pooled mean muscle mass loss of 8.9% in the first 5-7 days of PICU admission
• Using >10% loss as the threshold, 49.2% of children developed muscular atrophy
• Highlights that muscle wasting in critical illness is not confined to adults

2. Reviews (Narrative / Scoping)

• Covers the full arc from ICU to post-ICU: pre-existing sarcopenia/obesity, ICU complications, and recovery phase
• Key mechanisms identified: mitochondrial dysfunction, autophagy dysregulation, epigenetic modifications, cellular senescence, immune cell dysfunction, stem cell exhaustion, extracellular matrix remodeling
• Emphasizes that pathophysiology is dynamic - mechanisms differ between acute ICU phase and post-ICU recovery
• Proposes multi-approach treatments integrating nutritional, physical, and biological interventions

• Covers pathophysiology: systemic inflammation, immobilization, catabolic stress, mitochondrial dysfunction, immune dysregulation
• Discusses diagnosis: CT (gold standard), ultrasound, biomarkers, functional testing
• Emerging therapies: AI-based automated screening, NMES, targeted pharmacologic agents
• Highlights that ICU-acquired sarcopenia and myosteatosis remain under-recognized in routine practice

• Describes the "geriatric ICU phenotype": frailty, comorbidity, cognitive decline, malnutrition, sarcopenia, loss of autonomy, immunosenescence, and inflamm-aging acting together
• Sarcopenia contributes to worse short- and long-term prognosis beyond acute illness severity
• Argues for comprehensive geriatric assessment alongside standard ICU severity scores

• Reviews CT-measured psoas muscle area/density as a predictor of major adverse cardiac events and mortality in critically ill patients
• Positions psoas measurements as accessible, reproducible biomarkers from routine imaging

3. Randomized Controlled Trial

• Combined neuromuscular electrical stimulation (NMES) + high protein supplementation (mean 1.3 g/kg/day) + physical therapy vs. standard ICU care
• NMES+HPRO+PT group: less lower extremity muscle volume loss, larger thigh cross-sectional area, positive nitrogen balance on days 5/9/14, and significantly less delirium
• No difference in ICU LOS or mechanical ventilation days
• Supports combined intervention strategy for mitigating sarcopenia in mechanically ventilated patients

4. Observational/Diagnostic Studies

• Ultrasound-measured quadriceps thickness (rectus femoris + vastus intermedius) at 48h post-admission
• RF thickness negatively correlated with Charlson comorbidity index, NUTRIC score, NRS2002, and frailty index
• Confirms bedside ultrasound as a practical, useful tool for monitoring sarcopenia, nutritional status, and functional outcomes

• Measured rectus femoris and vastus intermedius thickness on day 3 and day 10 of ICU admission
• Rectus femoris lost ~2.9 cm, vastus intermedius ~2.6 cm over 7 days (statistically significant)
• Strain elastography ratio showed a trend toward increased muscle stiffness but did not reach significance
• Ultrasound confirmed as a practical, accessible bedside tool; elastography needs further study

• Low baseline muscle mass and poor skeletal muscle quality both associated with mortality in critically ill children

Key Takeaways from the Literature

USG Measurements of Quadriceps Muscle in the ICU

What Parameters Are Measured

Key Articles - Organized by Focus

Methodology & Standardization

• RF-CSA was used in 33/66 studies, QMLT in 32/66, RF thickness alone in 19/66
• Pooled RF-CSA at ICU admission: 2.83 cm² (95% CI: 2.29-3.37), but with extreme heterogeneity (I² = 98.43%)
• Higher age, higher BMI, more distal landmark placement, and probe compression all significantly reduced measured values
• Anatomical landmarks varied widely between studies - some measured at the midpoint of the anterior thigh, others at fixed distances from the patella or ASIS
• Conclusion: standardization of landmark, patient position, and probe compression is urgently needed before values can be compared across centres

• Rectus femoris thickness measured in 67.9% of studies, RF-CSA in 54.3%, vastus intermedius thickness in 40.2%
• Muscle quality parameters (echogenicity, pennation angle, fascicle length) used in a minority of studies
• 76.1% of studies performed serial measurements; 70.3% found significant muscle quantity depletion during ICU stay
• Lack of protocol standardization remains the main barrier to translating findings into clinical practice

Muscle Loss Quantification

• Measured RFCSA and QMLT on days 1, 3, and 7
• QMLT fell 5% by day 3 and 13% by day 7
• RFCSA fell 10% by day 3 and 27% by day 7 - CSA is more sensitive to early loss
• Lower caloric and protein intake correlated with greater muscle loss in the first 3 days
• QMLT reduction significantly predicted 28-day mortality: adjusted OR 1.088 per 0.1 cm reduction (95% CI: 1.018-1.113, p = 0.015)
• An 8.8% increase in odds of death per 0.1 cm reduction in QMLT

• Serial RF thickness at 48h (baseline) and day 7
• Mean 13.5% reduction in RF thickness over 7 days (p < 0.001)
• No change in thigh circumference - confirming ultrasound detects muscle loss more sensitively than anthropometry
• Greater loss in patients on mechanical ventilation, sedation, and in non-survivors
• Malnourished and eutrophic patients lost more muscle than overweight patients

• 16% reduction in RF-CSA (p = 0.002) and 24% reduction in pennation angle (p = 0.025)
• RF thickness, VI thickness, fascicle length changes were not statistically significant
• No association found between muscle loss and ICU LOS or 28-day mortality in this specific surgical cohort

Predicting ICU-Acquired Weakness (ICU-AW)

• Measured femoral CSA and femoral + vastus intermedius thickness (F+VIth) combined
• ICU-AW defined as MRC sum score < 48 at discharge; occurred in 28% of patients
• ICU-AW patients had significant reduction in F-CSA from day 1 to day 5 (p < 0.001)
• Day 1 F+VIth: AUC 0.82 for predicting ICU-AW - better discriminator than F-CSA alone (AUC 0.72)
• Key finding: low baseline muscle mass at admission (not the rate of subsequent loss) was the stronger predictor of ICU-AW, alongside high SOFA score

Post-ICU Trajectory

• After ICU discharge, group-level QMLT did not decline significantly - the major wasting phase occurs during the ICU stay itself
• Subgroup analysis: patients with poor nutritional intake and female sex continued to lose muscle after ICU discharge
• Physical function (MRC, grip strength) improved over time post-discharge
• Female sex and longer ICU LOS were predictors of impaired physical recovery

Reliability / Inter-rater Agreement

• Assessed inter-rater reliability of muscle ultrasound performed by multidisciplinary novice sonographers (not specialist radiologists)
• Supports feasibility of task-shifting muscle USG to physiotherapists and nurses after brief training

Summary of Practical Points from the Literature